Vanda Pharmaceuticals Inc. (VNDA)
Automate Your Wheel Strategy on VNDA
With Tiblio's Option Bot, you can configure your own wheel strategy including VNDA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VNDA
- Rev/Share 3.4403
- Book/Share 8.738
- PB 0.5024
- Debt/Equity 0.0144
- CurrentRatio 3.9251
- ROIC -0.1092
- MktCap 258722455.0
- FreeCF/Share -0.9806
- PFCF -4.508
- PE -5.8067
- Debt/Assets 0.0116
- DivYield 0
- ROE -0.083
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Vanda Pharmaceuticals Inc. (VNDA) Q1 2025 Earnings Call Transcript
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA ) Q1 2025 Results Conference Call May 7, 2025 4:30 PM ET Company Participants Kevin Moran - CFO Mihael Polymeropoulos - President, Chairman and CEO Tim Williams - Senior Vice President and General Counsel Conference Call Participants Andrew Tsai - Jefferies Charles Duncan - Cantor Fitzgerald Operator Good afternoon, and welcome to the Quarter One 2025 Vanda Pharmaceuticals Incorporated Earnings Conference Call. I am Franz, and I will be the operator assisting you today.
Read More
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Tops Revenue Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.07 per share a year ago.
Read More
Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"
Published: February 24, 2025 by: PRNewsWire
Sentiment: Neutral
WASHINGTON , Feb. 24, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of an article entitled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S" in Molecular Therapy Nucleic Acids1, a Cell Press partner journal, that describes the development of a novel antisense oligonucleotide (ASO) therapeutic, VCA-894A, for a patient with a rare variant in the IGHMBP2 gene causing Charcot-Marie-Tooth disease Type 2S (CMT2S). In 1886, Jean-Martin Charcot, Pierre Marie, and Henry Tooth independently described this hereditary motor and sensory neuropathy in their patients, paving the way for Charcot-Marie-Tooth (CMT) disease research.2,3 It was not …
Read More
Vanda Pharmaceuticals, Inc. (VNDA) Q4 2024 Earnings Call Transcript
Published: February 13, 2025 by: Seeking Alpha
Sentiment: Neutral
Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Kevin Moran - SVP, CFO & Treasurer Mihael Polymeropoulos - Founder, President, CEO & Chairman Conference Call Participants Charles Duncan - Cantor Fitzgerald Raghuram Selvaraju - H.C. Wainwright Andrew Tsai - Jefferies Operator Hello, and thank you for standing by.
Read More
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
Published: February 13, 2025 by: PRNewsWire
Sentiment: Neutral
Q4 2024 total revenues of $53.2 million, +17% compared to Q4 2023 Q4 2024 Fanapt® net product sales of $26.6 million, +18% compared to Q4 2023 Full year 2024 total revenues of $198.8 million, +3% compared to full year 2023 Full year 2025 revenue expected to grow to $210 to $250 million Psychiatry portfolio revenue expected to grow to greater than $750 million in 2030 Fanapt® MAA for bipolar I disorder and schizophrenia submitted in Q4 2024 BysantiTM (milsaperidone) NDA for bipolar I disorder and schizophrenia expected to be submitted in Q1 2025 HETLIOZ® MAA for Smith-Magenis syndrome submitted in …
Read More
About Vanda Pharmaceuticals Inc. (VNDA)
- IPO Date 2006-04-12
- Website https://www.vandapharma.com
- Industry Biotechnology
- CEO Dr. Mihael H. Polymeropoulos M.D.
- Employees 368